Figure 3
Figure 3. OS and CI of disease progression of patients with MDS associated with SF3B1 mutation. (A-B) Respectively, OS and CI of disease progression of MDS associated with SF3B1 mutation, defined by SF3B1 mutation, no excess blasts, or del(5q) (81 RARS, 48 RCMD-RS, 4 RA, or RCMD). (C-D), Respectively, OS and CI of disease progression of patients with MDS associated with SF3B1 mutation according to uni- or multilineage dysplasia (P values from multivariable analyses, OS: P = .5; CI of disease progression: P = .94). (E-F) Respectively, OS and CI of disease progression of patients with MDS associated with SF3B1 mutation according to RUNX1 mutation status (RUNX1 unmutated = 128, RUNX1 mutated = 5) (P values from multivariable analyses, OS: P = .018; CI of disease progression: P = .037).

OS and CI of disease progression of patients with MDS associated with SF3B1 mutation. (A-B) Respectively, OS and CI of disease progression of MDS associated with SF3B1 mutation, defined by SF3B1 mutation, no excess blasts, or del(5q) (81 RARS, 48 RCMD-RS, 4 RA, or RCMD). (C-D), Respectively, OS and CI of disease progression of patients with MDS associated with SF3B1 mutation according to uni- or multilineage dysplasia (P values from multivariable analyses, OS: P = .5; CI of disease progression: P = .94). (E-F) Respectively, OS and CI of disease progression of patients with MDS associated with SF3B1 mutation according to RUNX1 mutation status (RUNX1 unmutated = 128, RUNX1 mutated = 5) (P values from multivariable analyses, OS: P = .018; CI of disease progression: P = .037).

Close Modal

or Create an Account

Close Modal
Close Modal